Patents by Inventor Jonathan Edelson

Jonathan Edelson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220387299
    Abstract: The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof.
    Type: Application
    Filed: March 28, 2022
    Publication date: December 8, 2022
    Applicant: Anterios, Inc.
    Inventors: Jonathan Edelson, Timothy Kotyla, Klaus Theobald
  • Publication number: 20220296503
    Abstract: The present disclosure describes certain technologies for administering large agent(s) (e.g., biologically active large agents such as biologic therapeutics including, for instance, botulinum toxin) to subjects, including technologies that achieve unexpected results such as, for example, delayed peak effect and/or extended duration of response.
    Type: Application
    Filed: May 12, 2020
    Publication date: September 22, 2022
    Inventor: Jonathan Edelson
  • Publication number: 20220218623
    Abstract: Methods, compositions, and devices for enhancing transdermal delivery of large agents.
    Type: Application
    Filed: March 16, 2022
    Publication date: July 14, 2022
    Inventor: Jonathan Edelson
  • Publication number: 20220175634
    Abstract: The present invention provides nanoparticle compositions including one or more peptides. The present invention achieves transdermal delivery of such peptides without the need for peptide modification, or for use of chemical or mechanical abrasion or disruption of skin.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 9, 2022
    Applicant: Anterios, Inc.
    Inventors: Jonathan Edelson, Timothy Kotyla
  • Patent number: 11311496
    Abstract: Methods, compositions, and devices for enhancing transdermal delivery of large agents.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: April 26, 2022
    Assignee: Eirion Therapeutics, Inc.
    Inventor: Jonathan Edelson
  • Publication number: 20220105068
    Abstract: The present disclosures provides new technologies for treatment and/or prevention of certain dermatological conditions, specifically including graying hair. Among other things, the present disclosure provides an insight that plasminogen activator inhibitor-1 (PAI-1) inhibitors may be useful in the treatment and/or prevention of certain dermatological conditions, and in particular in treatment and/or prevention of graying hair.
    Type: Application
    Filed: September 12, 2019
    Publication date: April 7, 2022
    Inventor: Jonathan Edelson
  • Publication number: 20220079911
    Abstract: The present disclosures provides surprising insight into new technologies for treatment and/or prevention of certain types of hair loss (also known as alopecia), including androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, and senescent alopecia. Among other things, the present disclosure provides surprising insight that plasminogen activator inhibitor-1 (PAI-1) inhibitors may be surprisingly effective and/or useful in the treatment and/or prevention of certain types of hair loss, including androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, and senescent alopecia. Furthermore, the present disclosure provides insight that provided new technologies may not be particularly effective and/or useful in the treatment and/or prevention of other types of alopecia such as radiation-induced alopecia, chemotherapy-induced alopecia, and alopecia due to chronic discoid lupus erythematosus.
    Type: Application
    Filed: September 12, 2019
    Publication date: March 17, 2022
    Inventor: Jonathan Edelson
  • Publication number: 20220054389
    Abstract: The embodiment described herein are related nanoemulsions comprising botulinum toxins. In one embodiment, the nanoemulsions are prepared by high pressure microfluidization and comprise a particle size distribution exclusively between 10 and 300 nm. The nanoemulsions contemplated by the present invention are useful for the cosmetic and medical treatment of muscular contracture states. For example, botulinum toxin may relax facial muscles such that skin wrinkles become smoother and less noticeable. Further, the present invention contemplates a cosmetic formulation that may be self-administered, for example, in the privacy of one's home and without medical supervision.
    Type: Application
    Filed: March 8, 2021
    Publication date: February 24, 2022
    Applicant: University of Massachusetts Lowell
    Inventors: Jonathan Edelson, Robert Nicolosi
  • Publication number: 20220031595
    Abstract: Methods, compositions, and devices for enhancing transdermal delivery and/or bioavailability of large agents.
    Type: Application
    Filed: November 26, 2019
    Publication date: February 3, 2022
    Inventor: Jonathan Edelson
  • Publication number: 20210308021
    Abstract: The present invention provides nanoparticle compositions including one or more peptides. The present invention achieves transdermal delivery of such peptides without the need for peptide modification, or for use of chemical or mechanical abrasion or disruption of skin.
    Type: Application
    Filed: November 9, 2020
    Publication date: October 7, 2021
    Applicant: Anterios, Inc.
    Inventors: Jonathan Edelson, Timothy Kotyla
  • Patent number: 10905637
    Abstract: The present invention provides nanoparticle compositions including one or more peptides. The present invention achieves transdermal delivery of such peptides without the need for peptide modification, or for use of chemical or mechanical abrasion or disruption of skin.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: February 2, 2021
    Assignee: Anterios, Inc.
    Inventors: Jonathan Edelson, Timothy Kotyla
  • Publication number: 20200214961
    Abstract: The embodiment described herein are related nanoemulsions comprising botulinum toxins. In one embodiment, the nanoemulsions are prepared by high pressure microfluidization and comprise a particle size distribution exclusively between 10 and 300 nm. The nanoemulsions contemplated by the present invention are useful for the cosmetic and medical treatment of muscular contracture states. For example, botulinum toxin may relax facial muscles such that skin wrinkles become smoother and less noticeable. Further, the present invention contemplates a cosmetic formulation that may be self-administered, for example, in the privacy of one's home and without medical supervision.
    Type: Application
    Filed: December 13, 2019
    Publication date: July 9, 2020
    Inventors: Jonathan Edelson, Robert Nicolosi
  • Patent number: 10576034
    Abstract: The embodiment described herein are related nanoemulsions comprising botulinum toxins. In one embodiment, the nanoemulsions are prepared by high pressure microfluidization and comprise a particle size distribution exclusively between 10 and 300 nm. The nanoemulsions contemplated by the present invention are useful for the cosmetic and medical treatment of muscular contracture states. For example, botulinum toxin may relax facial muscles such that skin wrinkles become smoother and less noticeable. Further, the present invention contemplates a cosmetic formulation that may be self-administered, for example, in the privacy of one's home and without medical supervision.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: March 3, 2020
    Assignee: University of Massachusetts Lowell
    Inventors: Jonathan Edelson, Robert Nicolosi
  • Publication number: 20200054722
    Abstract: The present invention provides methods for improving observed or determined efficacy by administration of agents to more severely diseased subjects, as contrasted with less severely diseased subjects. The present disclosure specifically demonstrates that, with respect to treatment of certain skin conditions, and particularly conditions associated with dysregulated and/or diseased skin cells, administration to more severely diseased subjects improves observed or determined efficacy.
    Type: Application
    Filed: October 28, 2019
    Publication date: February 20, 2020
    Inventor: Jonathan Edelson
  • Patent number: 10532019
    Abstract: The embodiment described herein are related nanoemulsions comprising botulinum toxins. In one embodiment, the nanoemulsions are prepared by high pressure microfluidization and comprise a particle size distribution exclusively between 10 and 300 nm. The nanoemulsions contemplated by the present invention are useful for the cosmetic and medical treatment of muscular contracture states. For example, botulinum toxin may relax facial muscles such that skin wrinkles become smoother and less noticeable. Further, the present invention contemplates a cosmetic formulation that may be self-administered, for example, in the privacy of one's home and without medical supervision.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: January 14, 2020
    Assignee: University of Massachusetts Lowell
    Inventors: Jonathan Edelson, Robert Nicolosi
  • Patent number: 10485855
    Abstract: The present invention provides methods for improving observed or determined efficacy by administration of agents to more severely diseased subjects, as contrasted with less severely diseased subjects. The present disclosure specifically demonstrates that, with respect to treatment of certain skin conditions, and particularly conditions associated with dysregulated and/or diseased skin cells, administration to more severely diseased subjects improves observed or determined efficacy.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: November 26, 2019
    Assignee: Anterios, Inc.
    Inventor: Jonathan Edelson
  • Publication number: 20190343773
    Abstract: Methods, compositions, and devices for enhancing transdermal delivery of large agents.
    Type: Application
    Filed: September 25, 2017
    Publication date: November 14, 2019
    Inventor: Jonathan Edelson
  • Publication number: 20190183785
    Abstract: The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof.
    Type: Application
    Filed: October 18, 2018
    Publication date: June 20, 2019
    Inventors: Jonathan Edelson, Timothy Kotyla, Klaus Theobald
  • Patent number: 10016451
    Abstract: The present invention provides nanoparticle compositions including one or more nucleic acids. The present invention achieves delivery (particularly transdermal delivery) of such nucleic acids without the need for nucleic acid modification, or for use of chemical or mechanical abrasion or disruption of skin.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: July 10, 2018
    Assignee: Anterios, Inc.
    Inventors: Jonathan Edelson, Timothy Kotyla, Boke Zhang
  • Publication number: 20170312210
    Abstract: The embodiment described herein are related nanoemulsions comprising botulinum toxins. In one embodiment, the nanoemulsions are prepared by high pressure microfluidization and comprise a particle size distribution exclusively between 10 and 300 nm. The nanoemulsions contemplated by the present invention are useful for the cosmetic and medical treatment of muscular contracture states. For example, botulinum toxin may relax facial muscles such that skin wrinkles become smoother and less noticeable. Further, the present invention contemplates a cosmetic formulation that may be self-administered, for example, in the privacy of one's home and without medical supervision.
    Type: Application
    Filed: July 7, 2017
    Publication date: November 2, 2017
    Inventors: Jonathan Edelson, Robert Nicolosi